Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience.

Designed with patient comfort in mind, the Mynx immediately seals the arterial puncture site after a catheterization procedure using an extravascular, conformable sealant. The sealant, which consists of polyethylene glycol (PEG), is a water-soluble, bio-inert, non-thrombogenic polymer known for its well-established safety profile. PEG is commonly used in a wide range of medical products from gel caps to cranial sealing. Upon deployment, the sealant rapidly absorbs blood and subcutaneous fluids, swelling 3-4 times its size and sealing both the arterial puncture site and tissue tract. The sealant then dissolves completely through hydrolysis within 30 days, leaving nothing behind but a healed artery.

The Mynx offers a few key benefits over existing devices:

• Patient friendly
• Extravascular
• Clinically versatile
• Easy to use

Designed with the patient in mind, the unique deployment technique and novel sealant material of the Mynx help minimize the discomfort commonly associated with vascular closure. The device is deployed gently without the use of a suture or metal clip, avoiding cinching and tugging of the artery. Secondly, the sealant is placed on the outside of the artery, eliminating the need for an intra-arterial component or permanent metal implant.  The extravascular nature of the sealant seals the arterial puncture site on contact and provides a durable hemostasis.  Finally, due to its unique deployment technique, the Mynx can be used in a wide range of challenging cases typically not closed with existing closure devices.*

The Mynx Vascular Closure Device has both CE Mark and FDA approval and is available in two sizes for 5F and 6F/7F procedural sheaths. 
For more information, visit www.accessclosure.com